JP2023504016A5 - - Google Patents
Info
- Publication number
- JP2023504016A5 JP2023504016A5 JP2022530837A JP2022530837A JP2023504016A5 JP 2023504016 A5 JP2023504016 A5 JP 2023504016A5 JP 2022530837 A JP2022530837 A JP 2022530837A JP 2022530837 A JP2022530837 A JP 2022530837A JP 2023504016 A5 JP2023504016 A5 JP 2023504016A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- bcma
- cdr
- polypeptide chain
- chain comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024185441A JP7847630B2 (ja) | 2019-11-26 | 2024-10-21 | Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/120991 | 2019-11-26 | ||
| CN2019120991 | 2019-11-26 | ||
| CN2020111796 | 2020-08-27 | ||
| CNPCT/CN2020/111796 | 2020-08-27 | ||
| PCT/CN2020/131767 WO2021104371A1 (en) | 2019-11-26 | 2020-11-26 | Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185441A Division JP7847630B2 (ja) | 2019-11-26 | 2024-10-21 | Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504016A JP2023504016A (ja) | 2023-02-01 |
| JP2023504016A5 true JP2023504016A5 (https=) | 2023-12-01 |
| JP7773466B2 JP7773466B2 (ja) | 2025-11-19 |
Family
ID=76130007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022530837A Active JP7773466B2 (ja) | 2019-11-26 | 2020-11-26 | Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
| JP2024185441A Active JP7847630B2 (ja) | 2019-11-26 | 2024-10-21 | Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185441A Active JP7847630B2 (ja) | 2019-11-26 | 2024-10-21 | Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230002489A1 (https=) |
| EP (2) | EP4483895A3 (https=) |
| JP (2) | JP7773466B2 (https=) |
| KR (2) | KR20240162588A (https=) |
| CN (1) | CN114728065A (https=) |
| AU (2) | AU2020390288A1 (https=) |
| CA (1) | CA3160163A1 (https=) |
| IL (2) | IL293138A (https=) |
| MX (2) | MX2022006230A (https=) |
| TW (1) | TWI774137B (https=) |
| WO (1) | WO2021104371A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10519251B2 (en) * | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| EP4200336A4 (en) * | 2020-08-24 | 2024-09-25 | Epimab Biotherapeutics (HK) Limited | Anti-ror1 antibodies and related bispecific binding proteins |
| EP4413044A4 (en) * | 2021-10-07 | 2025-10-22 | Nat Res Council Canada | ANTI-CD3 MONOCLONAL ANTIBODIES AND THERAPEUTIC CONSTRUCTS |
| CN117003871A (zh) | 2022-04-28 | 2023-11-07 | 北京天广实生物技术股份有限公司 | 结合bcma和cd3的抗体及其用途 |
| TW202413405A (zh) * | 2022-07-13 | 2024-04-01 | 美商翰森生物有限責任公司 | 抗體、其抗原結合片段及其藥物用途 |
| WO2024074145A1 (zh) * | 2022-10-08 | 2024-04-11 | 盛禾(中国)生物制药有限公司 | 一种结合baffr和cd3的双特异性抗体及其应用 |
| EP4640700A1 (en) * | 2022-12-19 | 2025-10-29 | Harbour Biomed (Shanghai) Co., Ltd | "kappa/lambda" fab-fab series-connection multi-specific binding protein, preparation thereof, and use thereof |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117024596B (zh) * | 2023-08-18 | 2024-02-27 | 镜像绮点(上海)细胞技术有限公司 | 肿瘤原代细胞特异性标记与活体成像 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025131075A1 (zh) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | 抗cd3和抗cd3多特异性抗体及用途 |
| WO2025168059A1 (zh) * | 2024-02-08 | 2025-08-14 | 天劢源和生物医药（上海）有限公司 | 靶向bcma、cd19和cd3的多特异性抗原结合蛋白及其应用 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| KR101972446B1 (ko) * | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질 |
| WO2014122143A1 (en) * | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| IL263466B2 (en) * | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| US10519251B2 (en) * | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| EP2982692A1 (en) * | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3023437A1 (en) * | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| EP3916018A1 (en) * | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| US11421028B2 (en) * | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| JP7033328B2 (ja) * | 2016-08-16 | 2022-03-10 | エピムアブ バイオセラピューティクス インコーポレイテッド | 一価の非対称タンデムＦａｂ二重特異性抗体 |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| KR102820804B1 (ko) * | 2017-09-22 | 2025-06-16 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체 |
| JP2021508479A (ja) * | 2017-12-27 | 2021-03-11 | テネオバイオ， インコーポレイテッド | ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン |
| EP3788079A4 (en) * | 2018-05-03 | 2022-12-21 | Shanghai Epimab Biotherapeutics Co., Ltd. | ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF |
| UA130542C2 (uk) * | 2018-05-16 | 2026-03-18 | Янссен Байотек, Інк. | Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта |
-
2020
- 2020-11-26 JP JP2022530837A patent/JP7773466B2/ja active Active
- 2020-11-26 AU AU2020390288A patent/AU2020390288A1/en active Pending
- 2020-11-26 IL IL293138A patent/IL293138A/en unknown
- 2020-11-26 KR KR1020247036665A patent/KR20240162588A/ko active Pending
- 2020-11-26 CN CN202080081975.5A patent/CN114728065A/zh active Pending
- 2020-11-26 TW TW109141514A patent/TWI774137B/zh active
- 2020-11-26 EP EP24211210.0A patent/EP4483895A3/en active Pending
- 2020-11-26 CA CA3160163A patent/CA3160163A1/en active Pending
- 2020-11-26 WO PCT/CN2020/131767 patent/WO2021104371A1/en not_active Ceased
- 2020-11-26 KR KR1020227021084A patent/KR20220104783A/ko active Pending
- 2020-11-26 IL IL316618A patent/IL316618A/en unknown
- 2020-11-26 US US17/776,167 patent/US20230002489A1/en active Pending
- 2020-11-26 MX MX2022006230A patent/MX2022006230A/es unknown
- 2020-11-26 EP EP20892443.1A patent/EP4065164A4/en active Pending
-
2022
- 2022-05-23 MX MX2024013229A patent/MX2024013229A/es unknown
-
2024
- 2024-10-21 JP JP2024185441A patent/JP7847630B2/ja active Active
- 2024-12-12 AU AU2024278367A patent/AU2024278367A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023504016A5 (https=) | ||
| JP2021522347A5 (https=) | ||
| JP2023002615A5 (https=) | ||
| JP2023538945A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| JP2022515318A5 (https=) | ||
| JP2021522162A5 (https=) | ||
| JP2021530251A5 (https=) | ||
| JP2018503380A5 (https=) | ||
| JP2021501162A5 (https=) | ||
| JP2024056687A5 (https=) | ||
| JP2020522254A5 (https=) | ||
| JP2018522888A5 (https=) | ||
| JP2018523493A5 (https=) | ||
| RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
| RU2018106452A (ru) | Поливалетные и полиспецифичные gitr-связывающие слитые белки | |
| JP2017535257A5 (https=) | ||
| JP2021508707A5 (https=) | ||
| JP2021520832A5 (https=) | ||
| JP2018507188A5 (https=) | ||
| JP2020533016A5 (https=) | ||
| JP2021531255A5 (https=) | ||
| JP2023509214A5 (https=) | ||
| JP2023549316A5 (https=) | ||
| JP2023545521A5 (https=) |